Adoptive T cell therapy uses the specificity of the adaptive immune system to target cancer and virally infected cells. Yet the mechanism and means by which to enhance T cell function are incompletely described, especially in the skin. In this study, we use a murine model of immunotherapy to optimize cell-mediated immunity in the skin. We show that in vitro-derived central but not effector memory-like T cells bring about rapid regression of skin-expressing cognate Ag as a transgene in keratinocytes. Local inflammation induced by the TLR7 receptor agonist imiquimod subtly yet reproducibly decreases time to skin graft rejection elicited by central but not effector memory T cells in an immunodeficient mouse model. Local CCL4, a chemokine liberated by TLR7 agonism, similarly enhances central memory T cell function. In this model, IL-2 facilitates the development in vivo of effector function from central memory but not effector memory T cells. In a model of T cell tolerogenesis, we further show that adoptively transferred central but not effector memory T cells can give rise to successful cutaneous immunity, which is dependent on a local inflammatory cue in the target tissue at the time of adoptive T cell transfer. Thus, adoptive T cell therapy efficacy can be enhanced if CD8 + T cells with a central memory T cell phenotype are transferred, and IL-2 is present with contemporaneous local inflammation. The Journal of Immunology, 2012, 189: 5622-5631.
E pithelial cancers and chronic viral infections at epithelial surfaces represent a significant cause of morbidity and mortality worldwide (1, 2) , for which adoptive transfer of ex vivo-activated Ag-specific T cells is mooted as potential therapy. Adoptive T cell transfer, which uses the specificity of the TCR, conveys an advantage over immunization, because individual Ag-specific CD8 + T cells of high affinity can be expanded ex vivo to produce large numbers of cytotoxic effector precursors. Adoptive cell therapy holds great promise for the treatment of epithelial cancers and chronic viral infections (3) . However, the reported success rates for adoptive cell therapy in humans are highly variable, ranging between 20 and 70% (4) (5) (6) . The variable response observed to adoptive immunotherapy suggests a need to better understand the requirements for optimization of in vivo outcomes after adoptive transfer of T cells.
Once activated, naive CD8 + T cells differentiate into short-lived CD44 hi CD62L lo effector and effector memory T cells (T EFF /T EM ), or lymphoid organ-residing CD44 hi CD62L hi central memory T cells (T CM ) (3) . Previous work investigating the means by which to optimize T cell therapy has shown that, although T EFF /T EM demonstrate the capacity for rapid target lysis, the in vivo durability of T CM make this cell type best suited for use in adoptive cell therapy (7, 8) . However, the mechanisms underlying enhanced outcomes with T CM and the means by which to further augment the function of T CM are poorly understood. Furthermore, the relative potential of T EM and T CM in adoptive cell therapy targeted to the skin has not been described. CD8 + T cell-mediated immunity occurs in a tissue-specific manner. CD8 + T cell activation via s.c. immunization, for example, induces activated T cells that home to skin (9) . Thus, optimization of immunotherapy for cutaneous viral infection and malignancy requires an understanding of the immunobiology of adoptively transferred T cells in skin-specific immunotherapy. We have used a system in which murine skin expressing a model Ag is grafted onto a naive host to study the requirements for effective skin-targeted immunotherapy (10) (11) (12) (13) . In this system, a model Ag, such as OVA or the viral oncogene E7, is expressed as a transgene in keratinocytes under the control of basal keratinocyte-specific promoters for the genes keratin 5 or keratin 14. In the case of OVA, this system models the immune consequences of Ag expression in epithelial cells without the confounding effects of tumor-related immune modulation. Rejection of the transgenic graft is easily visualized and is a measure of local immune effector function (12) . This system allows investigation of induction of immune responses by Ag expressed in skin and effector functions elicited within this site by endogenous or adoptively transferred naive T cells (10) (11) (12) (13) . In this study, we investigate the capacity of different populations of ex vivo-activated memory T cells to elicit immune effector functions in the skin and the requirements for an optimal response.
Materials and Methods

Mice
C57BL/6 and Rag1
2/2 mice were sourced from the Animal Resources Centre (WA, Australia). TCR transgenic mice specific for H-2k b -bound SIINFEKL peptide (OT-I mice) were originally sourced from W. R. Heath (University of Melbourne, Parkville, VIC, Australia). K5mOVA transgenic C57BL/6 mice, in which OVA, is expressed under control of the keratin 5 promoter, were provided by H. Azukizawa (Osaka University, Osaka, Japan) (14) . CD11c.OVA mice, in which OVA expression is under the CD11c promoter, were bred at the Biological Resources Facility (Brisbane, QLD, Australia). All mice were housed under specific pathogen-free conditions, used at 6-10 wk of age, and sex-matched for all experiments. All animal procedures were approved by the University of Queensland Animal Ethics Committee.
Flow cytometry and intracellular Ag staining mAbs to murine CD8, CD3, CD44, CD62L, IFN-g, T-bet, IL-2, and associated Ig controls were purchased from BD Biosciences (San Jose, CA) and eBioscience (San Diego, CA) and used as per manufacturers' protocol. For intracellular cytokine staining, cells were stimulated with 25 ng/ml PMA (Sigma-Aldrich, Castle Hill, NSW, Australia) and 1 mg/ml ionomycin (Sigma-Aldrich) and monensin (BioLegend, San Diego, CA). Permeabilization, fixation, and staining were performed as per the manufacturer's instructions (Mouse Intracellular Cytokine Staining Kit; BD Biosciences). Staining of the transcription factor T-bet was performed with fixation and permeabilization reagents from the Foxp3 staining kit as per the manufacturer's instructions (BD Biosciences). Data were acquired using the FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo version 8.7.3 (Tree Star, Ashland, OR).
Skin grafting
Ear skin was grafted onto the flanks as described previously (12, 15) . Briefly, donor ear epidermis was placed onto graft beds of 1 cm 2 on the flanks of anesthetized mice and fixed with Elastoplast fabric strips (Beiersdorf, North Ryde, NSW, Australia). Bandages were removed 7 d later, and grafts were allowed to heal completely for 6 wk during which time all inflammatory cytokines return to resting levels (16, 17) . Grafts were considered rejected when .80% of the graft area was visibly ulcerated and necrotic.
Imiquimod treatment
Skin grafts were treated with 30 mg 5% imiquimod cream (Aldara; iNova Pharmaceuticals, Thornleigh, NSW, Australia) under occlusive dressing for 10 consecutive days or until rejection occurred (15) . Aqueous cream (Sorbolene; Redwin Skin Care, Moorabbin, VIC, Australia) was applied as a control.
Central and effector memory T cell culturing and adoptive transfer
An existing protocol was modified for in vitro differentiation of T CM and T EM from wild-type, Ag-naive OT-I mice at 6-8 wk of age (18) . For differentiation of T EM , splenocytes from naive OT-I mice were cultured overnight with 100 ng/ml SIINFEKL peptide, washed, and then grown with 20 ng/ml rIL-2 (PeproTech, Rocky Hill, NJ). T CM were differentiated similarly using lymphocytes from naive OT-I mice and, following peptide exposure, were cultured with 10 ng/ml rIL-7 and IL-15 (PeproTech). All cells were grown in RPMI 1640 medium (Gibco, Carlsbad, CA) supplemented with 10% FCS (Bovogen, Keilor East, VIC, Australia). Prior to tail vein adoptive transfer, nonviable cells were eliminated by centrifugation with Histopaque 1077 as per the manufacturer's instructions (Sigma-Aldrich).
Lymphocyte purification from skin and liver
Skin grafts were excised and incubated in 1 mg/ml collagenase at 37˚C for 3 h with mechanical dissociation. Cells were then strained and resuspended in buffer containing 5% FCS. Single-cell suspensions of liver cells were purified with a 32% Percoll gradient (GE Healthcare, Uppsala, Sweden) as per the manufacturer's instructions, and RBCs were removed with the use of ACK (Ammonium-Chloride-Potassium) Lysing Buffer (Life Technologies, Grand Island, NY).
mAb production and treatment
Anti-CD8 (Ab 53-5.8) was produced from hybridoma cell lines using a sequential serum dilution technique as described previously (15) . For grafting experiments, 100 mg 53-5.8 in PBS was injected i.p. on the day prior to skin grafting. On days 2 and 7, postgrafting animals were treated with an additional 150 mg 53-5.8. On day 9 postgrafting, CD8 + T cell depletion was assessed by analysis purification of leukocytes from a peripheral eye bleed stained with CD3 and CD8a. Anti-IL-2 rat IgG mAbs from clones S4B6 and Jes6-1A12 were sourced from BioXCell (West Lebanon, NH), a fermentation and purification service that produces endotoxin-negative in vivo-verified Abs. One hundred micrograms of both S4B6 and Jes6-1A12 were injected daily for 10 d from the day of cell transfer as described previously (19) .
In vitro cytotoxicity assay
Cytotoxicity assay was performed as described previously (20 
Chemokine injection and chemokine receptor antagonists
All recombinant chemokines were sourced from PeproTech. The chemokine antagonist CCL5 and inert control peptide CCL2 (4Ala) were synthesized as described previously (21) . Mice were treated with 100 mg CCL5 or the inert control peptide CCL2 (4Ala) via i.p. injection every other day following day 4 postgrafting. The in vivo activity of this antagonist has been validated as described previously (22) .
Statistics
Skin graft survival curves were depicted on Kaplan-Meier curves and logrank tests performed to assess statistical significance differences in survival. All data were analyzed by Prism Version 4 (GraphPad, San Diego, CA).
Results
Ag-specific CD8
+ T cells are necessary and sufficient for K5mOVA skin graft rejection Rejection of skin grafts expressing non-self-Ag from a keratin promoter has been used to study T cell immunotherapy (12, 15, 23) . We studied the capacity of T cells to mediate rejection of skin grafts expressing OVA from the keratin 5 promoter (henceforth, K5mOVA mice) (14) . Newly placed K5mOVA skin grafts were rejected spontaneously by naive, immunocompetent C57BL/6 animals but not by lymphodeplete Rag1 2/2 animals and not by wild-type animals depleted of cells expressing the CD8 chain, confirming that K5mOVA graft rejection is dependent on CD8 + T cell effector function ( A local inflammatory cue enhances skin graft rejection by activated CD8 + T cells
Using a papillomavirus Ag, HPV16 E7 protein, expressed as a transgene in skin grafts, we have previously demonstrated that healed grafts are less effectively rejected by transferred Ag-specific T cells than newly placed grafts (12) . To investigate whether local inflammation alters the efficiency of Ag-experienced CD8 + T cells in skin graft rejection, mice were primed to OVA by placement of a K5mOVA graft, which was rejected. Subsequently, these mice were depleted of CD8 + T cells, and given two additional K5mOVA grafts, which were not rejected. After T cell recovery, a third K5mOVA graft was given, and one of the two well-healed grafts was treated with imiquimod. The newly placed graft was rejected, confirming restoration of functional OVA-specific T cells. The imiquimod-treated healed graft was rejected more rapidly than the untreated graft (Fig. 1C) , demonstrating that local inflammation contributes to immune effector function. To confirm that imiquimod alone does not induce rejection of K5mOVA skin, Rag1 2/2 mice bearing well-healed K5mOVA grafts were treated with imiquimod or control cream; neither resulted in grafts being rejected (Supplemental Fig. 1 ). To investigate the mechanism by which local inflammation could enhance CD8
+ effector function, we first studied whether activated, adoptively transferred, Ag-specific CD8 + T cells could promote graft rejection in the absence of other lymphocytes. Rag1 2/2 animals received two K5mOVA skin grafts and were allowed to heal for 6 wk. Following healing, grafted animals received an adoptive transfer of OT-I splenocytes and s.c. immunization with OVA/Quil A. When one of the two healed K5mOVA grafts was treated with topical imiquimod, rejection of the treated graft was significantly faster than rejection of the untreated graft across a range of OT-I cell precursor frequencies ( Fig. 1D-F ). The effect of imiquimod on graft rejection was most pronounced at the lowest number ( 10 5 ) of OT-I transferred cells, indicating the capacity of imiquimod to enhance suboptimal responses. In these immunized animals, two distinct populations of activated CD8 + T cells could be demonstrated: CD44 hi CD62L lo T cells of T EM phenotype and CD44 hi CD62L hi T cells of T CM phenotype (Supplemental Fig. 2 ).
Local TLR7 ligation augments cutaneous immunotherapy elicited by T CM but not T EM
We next aimed to determine which subset of adoptively transferred, activated CD8 + T cells (T EM or T CM -phenotype cells) were responsible for the accelerated rejection induced by topical imiquimod. Modification of an existing protocol (18) using nonimmunized wild-type OT-I lymphocytes was implemented for the ex vivo production of T CM and T EM . OT-I cells differentiated in the presence of IL-7 and IL-15 were CD44 hi CD62L hi and expressed IFN-g and TNF-a but failed to express granzyme B after stimulation with PMA/ionomycin, consistent with a T CM -like phenotype ( Fig. 2A-E) . In contrast, cells differentiated in the presence of IL-2 showed a morphology consistent with fully differentiated T EFF /T EM (compare Fig. 2G, 2H ) and were CD44 hi and CD62L lo T EM -like cells and expressed high levels of IFN-g, granzyme B, and TNF-a ( Fig. 2A-E) . The putative T EM population expressed high levels of T-bet, whereas the T CM and naive cell populations expressed intermediate and low levels of T-bet, respectively (Fig. 2F) .
In vitro-differentiated T EM exhibited enhanced in vitro killing capacity as compared with T CM (Fig. 2I, 2J ). In vitro-differentiated memory T cell populations, therefore, demonstrated the functional and phenotypic attributes held characteristic of T EM -and T CMlike cells.
To compare the capacity of T EM and T CM T cell subsets to induce skin graft rejection, and the extent to which this was enhanced by local inflammation, Rag1 2/2 mice bearing two well-healed K5mOVA grafts received in vitro-differentiated T CM or T EM , and one of the two grafts was treated with topical imiquimod. Rejection of the K5mOVA skin grafts was significantly quicker in recipients of T CM than in recipients of equivalent numbers of T EM (Fig. 3) . Furthermore, grafts treated with topical imiquimod on animals recipient of T CM showed accelerated rejection compared with untreated grafts, whereas this was not observed for animals recipient of T EM . The effect of rapid T CM -mediated graft rejection augmented by imiquimod was consistently observed across a range of transferred OT-I T CM and T EM frequencies.
T CM persist to a greater extent than T EM in both lymphodeplete and lymphoreplete environments
We next investigated whether T CM -mediated graft rejection was a consequence of prolonged OT-I T cells survival in vivo. In vitrodifferentiated T CM and T EM were transferred into Rag1 2/2 mice bearing well-healed K5mOVA skin grafts. Given that lymphodeplete environments can prolong survival of transferred T cells through the availability of homeostatic cytokines (24) , T CM and T EM were also transferred into lymphoreplete Rag.2C mice bearing well-healed K5mOVA skin grafts -Rag.2C mice possess a complement of functional T cells solely specific for the SIYR-YYGL alloepitope. Forty-five days following transfer, the spleen, lymph nodes, and the liver were harvested, processed into single- cell suspensions, stained for CD8, Va2, and CD62L, and analyzed by flow cytometry. Fig. 4A, 4C, (Fig. 4B, 4D, 4F ).
Inhibition of IL-2 mitigates enhanced rejection by T CM
Autocrine production of IL-2 has been shown to drive the secondary expansion and survival of T CM (25) . Fig. 5A and 5B show that in vitro-differentiated T CM but not T EM produce large amounts of IL-2 upon stimulation with PMA/ionomycin. We thus hypothesized that IL-2 played a role in enhancing T CM -mediated graft rejection. Treatment with IL-2-inhibiting mAbs JES6-1 and S4B6 was associated with significantly delayed well-healed K5mOVA graft rejection in recipients of T CM but not T EM (Fig.  5C ). Furthermore, inhibition of IL-2 binding to the high-affinity IL-2Ra, CD25, by JES6-1 alone also delayed T CM -mediated skin graft rejection to that same extent as combination of JES6-1 and S4B6, which blocks IL-2 completely (Fig. 5D ). This confirms a role for autocrine IL-2 signaling through the trimeric highaffinity IL-2R complex in the acquisition of effector function by T CM but not T EM . Lymphoreplete environments have been reported to inhibit adoptive cell therapy by decreasing the availability of g-chain cytokines to adoptively transferred, effector-phenotype cells (24) . Given that T CM are able to produce the g-chain cytokine, IL-2, we proposed that T CM but not T EM would reject skin grafts in lymphoreplete environments. Fig. 5E shows that T CM but not T EM -rejected well-healed K5mOVA skin grafts in lymphoreplete Rag.2C animals.
Intradermal CCL4 but not CCL2 nor CXCL2 is sufficient to recapitulate the effect of imiquimod on T CM -mediated graft rejection
We next examined the mechanism by which imiquimod enhances T CM -mediated graft rejection. Imiquimod treatment of the flank of C57BL/6 mice induces a dense inflammatory infiltrate into the epidermis and dermis (Fig. 6A, 6B ). To assess whether imiquimod increased trafficking of T CM -derived cells into inflamed skin, Rag1 2/2 mice bearing two well-healed K5mOVA skin grafts were adoptively transferred with 10 5 CFSE-labeled T CM , and one of the two grafts was treated daily with imiquimod. Analysis of single-cell suspensions of skin grafts by flow cytometry on day 5 posttransfer showed imiquimod increased T cell traffic into imiquimod-inflamed skin. All cells analyzed were CFSE negative, indicating that these cells were divided progeny of transferred T CM , because Rag1 2/2 mice have no endogenous T cells (Fig. 6C) . We next hypothesized that local inflammation could enhance graft rejection in part via inflammatory chemokines We have previously shown in a microarray screen that local imiquimod application upregulates the expression of the chemokines CCL2, CXCL2, and CCL4, all of which are known to induce T cell trafficking (15, 26, 27) . To determine whether chemokines alone could enhance graft rejection, one of two grafts on Rag1 2/2 animals bearing well-healed K5mOVA grafts that received in vitro-differentiated T CM were injected s.c. with rCCL2, CXCL2, or CCL4, and the other with vehicle control. Only CCL4 accel- erated rejection of grafts mediated by T CM , and this was in a dosedependent fashion (Fig. 6D-G) . If CCL4 was the only determinant of imiquimod-enhanced T CM -mediated graft rejection, then we predicted that blockade of the dominant CCL4 receptor CCR5 would reverse imiquimodenhanced graft rejection. However, inhibition of CCR5, using a small peptide antagonist (CCL5 ) failed to alter the effects of imiquimod on T CM -mediated graft rejection (Fig. 6H) , even though this antagonist is able to inhibit CCL4-mediated migration of CD8 + T cells in vitro and T cell-dependent delayed-type hypersensitivity reactions in vivo (Fig. 6I, 6J ).
Local TLR7 stimulation and adoptive transfer of T cells are sufficient to overcome tolerance of skin-expressed Ag
Therapy mediated by adoptively transferred Ag-specific T cells may be inhibited by tolerance (28) (29) (30) (31) (32) (33) . To investigate whether local inflammation might overcome tolerance induced in adoptively transferred T cells, we used CD11c.OVA mice, in which expression of OVA in dendritic cells from the CD11c promoter in dendritic cells induces tolerance in adoptively transferred OVAspecific memory T cells (34) (35) (36) . K5mOVA skin grafts were not rejected by CD11c.OVA mice, consistent with the impaired response of this transgenic mouse strain to OVA (Fig. 7A) (34) . CD11c.OVA mice bearing bilateral well-healed K5mOVA skin grafts received an adoptive transfer of either T CM or T EM , and one graft was treated daily with imiquimod. Animals that received OVA-specific T CM rejected only the grafts treated with imiquimod, whereas animals that received OVA-specific T EM did not reject grafts, whether treated with imiquimod.
OVA-specific T cells transferred to CD11c.OVA mice more than 4 wk previously are fully tolerized (34) . To demonstrate whether such tolerance could be overcome by local proinflammatory signals, we grafted CD11c.OVA mice with K5mOVA skin. When grafts were healed, animals received OVA-specific T CM by adoptive transfer. After an additional 30-d grafts were treated with imiquimod, and no rejection was observed (Fig. 7B) . Thus, once tolerance is established, local inflammation can no longer establish a successful adaptive immune response mediated by T CM .
Discussion
In this study, we demonstrate that cells differentiated in vitro to acquire T CM characteristics exhibit more rapid in vivo cutaneous immune effector function, manifest as rejection of transgenic skin, than those differentiated to T EM . Rapid T CM -but not T EM -mediated graft rejection is mitigated by the inhibition of IL-2. We further show that T CM -mediated graft rejection is enhanced by local inflammation induced by a TLR7 ligand or by the local provision of the chemokine CCL4. In contrast, graft rejection mediated by T EM is not significantly enhanced by TLR7 ligation. Local inflammation in skin allows T CM effector capacity in a tolerogenic environment that is otherwise induced by presentation of cognate Ag by APC.
The long-lived nature and rapid responses of memory T cells has led to the proposal that these cells are the most appropriate for T cell-based immunotherapies (37) . The ability of local inflammation to enhance the development of fully competent T effector cells from memory T cell populations, as demonstrated in this study using parallel transgenic graft targets, has only recently been recognized, yet no studies have investigated the effect of local inflammation on T CM -and T EM -mediated immune responses (38) (39) (40) (41) . Local TLR7 ligation augments rejection of human growth hormone transgenic skin grafts from a graft-primed animal (15) . Well-healed grafts expressing the E7 protein of human papillomavirus are, unlike newly placed and inflamed grafts, protected against rejection by E7-specific CTL passively transferred and primed in vivo (12) . In this study, we show that time to effective T CM -mediated immune response in skin is decreased by local inflammation, whereas T EM -mediated immune responses are not affected. Traditionally, T EM , which express cytotoxic molecules, such as granzyme B, and demonstrate enhanced in vitro cytotoxicity, have been considered the ideal cell type for adoptive immunotherapy (42, 43 ). Yet, T CM have been reported to mediate disease in mouse model of skin graft versus host disease (44) , and T CM mediate regression of transplanted melanoma in mice more effectively than T EM (45) , which is considered a product of their prolonged in vivo persistence (46) . Likewise, recently described human and murine T memory stem cells possess prolonged in vivo persistence that has been attributed to comprehensive regression of established tumors in mice and may hold future therapeutic promise in humans (47, 48) .
We have previously demonstrated generation of enhanced effector function for skin graft rejection following systemic administration of the TLR4 agonist LPS in wild-type mice (49) . In this study, we show that an inflammatory cue provided at the effector site decreases the time to CD8 + T CM -mediated attack in immunodeficient mice. Although the effect of imiquimod in enhancing T CM -but not T EM -mediated graft rejection is subtle, the effect is consistently reproducible across multiple different cell precursor frequencies and multiple conditions. Rejection of skin grafts in the tolerogenic CD11c.OVA environment is, furthermore, dependent on a local inflammatory cue. This may indicate that 2/2 mice bearing bilateral well-healed K5mOVA skin grafts were adoptively transferred with T CM and treated with the CCR5-inhibiting peptide CCL5 or the nonfunctional mutated chemokine CCL2 (4Ala) , whereas one of the two grafts was treated with imiquimod. Grafts were then monitored for rejection and plotted on a Kaplan-Meier survival curve. n = 8 for all groups. **p , 0.01, ***p , 0.001, log-rank test. (I) Transwell migration assay of purified CD8 + T cells stimulated with CD3 and CD28 mAbs, migrating in response to CCL4. Inhibition of T cell migration by CCL5 9-68 was evaluated by increasing concentration of CCL5 and assessing the percentage of migrated cells relative to wild-type CCL4. Nonfunctional CCL2 4Ala peptide was used as control. n = 2. *p , 0.05 by one-way ANOVA. (J) Delayed-type hypersensitivity reaction was established by tail-base immunization of C57BL/6 mice with OVA in CFA. Seven days later, a recall was conducted in a footpad, and an increase in footpad thickness was assessed by calipers. To assess for in vivo activity of CCL5 9-68 , 1 d prior to recall animals were treated with CCL5 9-68 or control peptide CCL2 4Ala . Data are presented as mean 6 SEM. Data were analyzed by a Student t test. n = 12/group. *p , 0.05. the primary role of inflammation in augmenting effector T cell responses is in influencing other adaptive immune cells. Local enhancement of effector function by local proinflammatory signaling through TLRs might also reflect increased recruitment of effectors (41), increased proliferation and maturation (50) of effector precursors, and/or induction of helper functions that override local inhibitors in skin (51) . Local inhibitors include the antiinflammatory cytokines IL-10 and TGF-b; NKT cells are also inhibitory in skin through an IFN-g-dependent mechanism (10, 11, 52, 53) .
Imiquimod can induce T cell migration to inflamed sites presumably through upregulation of chemokines and cellular adhesion molecules (15, (54) (55) (56) (57) . CCL4, CCL2, and CXCL2 expression is increased in imiquimod-inflamed skin (15), we show in this paper that only intradermal injections of CCL4 but not CCL2 and not CXCL2 are able to recapitulate the effects of imiquimod. However, inhibition of CCL4 through a small peptide antagonist that binds to the dominant CCL4 receptor CCR5 does not reverse imiquimod-augmented graft rejection. The lack of effect of the CCR5 antagonist indicates a potential redundancy in the chemoattractive molecules dictating effector T cell migration to the skin (58) . Further analyses of the differential expression of chemokines and chemokine receptors seen on T CM effector progeny and T EM may further elucidate such redundancy.
Enhancement of graft rejection by local inflammation was specific to T CM and inhibited by blockade of IL-2 signaling. A role for IL-2 in augmenting T CM -but not T EM -mediated effector function has been proposed but not experimentally shown (59) . In this study, we show that CD8 + T cells differentiated in the presence of IL-15 and IL-7 but not IL-2 produce IL-2 upon stimulation. Blocking IL-2-mediated signaling with mAbs prolongs T CMmediated effector function manifest as delayed graft rejection where the time to rejection is similar that observed in recipients of T EM . Given that autocrine production of IL-2 has been shown to drive secondary expansion of memory T cells (25) , the likely effect of IL-2 in this model is to induce T CM proliferation. Signaling through the trimeric high-affinity IL-2R complex has been shown to cause proliferation as opposed to maintain T cell number (19) . This is of consequence given that we have shown there that inhibition of signaling through the high-affinity trimeric IL-2R complex prolongs T CM -mediated graft survival.
T CM phenotype cells induce more complete regression of transplantable melanoma than T EM (45) , and it has been postulated that enhanced in vivo reactivity against tumors by T CM is a product of lymph node homing and prolonged in vivo survival (45, 46) . In this study, we confirm that T CM persist to a greater extent in vivo than T EM . We further previous observations in showing that persistence of T CM is seen across multiple lymphoid organs. This is significant given that the liver has been shown to be a niche for T EM /T EFF T cells (60) , yet in our study, the number of T CM in liver at day 45 following transfer is greater than that of T EM . We further show that 45 d following transfer into grafted hosts, T CM possess the capacity to differentiate into CD62L hi central memory phenotype cells. Maintenance of large populations of in vitro-derived T cells following transfer is thought to be a product of homeostatic g-chain cytokines present in lymphopenic hosts (24) . We transferred T CM into both lymphodeplete (Rag1
) and lymphoreplete (Rag.2C) hosts and failed to see a significant difference in the persistence of T CM , whereas the number of persisting T EM was too small to conclude any significant difference Rag1 2/2 and Rag.2c mice.
Moreover, we show that T EM failed to reject grafts in Rag.2C lymphoreplete mice. Thus, the capacity of T CM to persist and reject skin grafts in both lymphodeplete and lymphoreplete environments may be a consequence of intrinsic T CM programming and cytokine production. Jensen and colleagues (8) recently proposed that host-produced IL-15 contributes to persistence of adoptively transferred human TCM in a lymphodeplete mouse model. In our study, T CM differentiated in the presence of IL-15 produced IL-2, whereas T EM differentiated in the presence of IL-2 did not produce autocrine IL-2. Our data indicated that autocrine IL-2 production is a consequence of IL-15 stimulation and may play a pivotal role in the effector function of T CM progeny. In current adoptive cell therapy strategies used in humans, IL-2 is administered along with effectorphenotype cells to prolong the persistence adoptively transferred cells (2) . IL-2, however, has significant adverse effects including cardiomyopathy and pleural effusion (61) . The use of T CM , which self-produce IL-2 and display enhanced in vivo persistence, may obviate the need for exogenous use of IL-2 in the clinic.
Failure of adoptive immunotherapeutic regimes may be accounted for by the tolerogenic effects of malignant disease (28, 29, 31-35, 62, 63) . To address the effects of tolerance induction, we used the CD11c.OVA murine model. This mouse strain lacks a functional OVA-responsive repertoire and induces tolerance in adoptively transferred naive and memory CD8 + T cells (34) (35) (36) . In this model, we show that adoptive transfer of Ag-specific T cells alone did not reject K5mOVA skin grafts. Rather, only skin grafts that were inflamed by imiquimod in animals that had received T CM were rejected. Imiquimod treatment could not overcome established tolerance as treating skin grafts with imiquimod after T CM had undergone tolerance induction failed to induce graft rejection. Other approaches to breaking or preventing tolerance have used CD40, IL-2, and CD4 + T cell-based regimens. Our method using contemporaneous proinflammatory signals and T cell transfer may complement these (38, (64) (65) (66) and provides a means to enhance the efficacy of skin-directed adoptive immunotherapy in a potentially tolerogenic environment. Holcmann et al. (67) reported that skin inflammation alone does not break tolerance and cause skin disease when naive CD8 + T cells are adoptively transferred into animals that express tamoxifen-inducible K5mOVA (68) . This disparity may be accounted for by the observation that memory and naive CD8 + T cells display differing sensitivities to tolerance induction (34, 35, 62) .
The mechanisms by which imiquimod breaks tolerance in the skin are currently under investigation. Imiquimod-inflamed skin tumors in humans possess decreased number of regulatory T cell (T Reg ) cells (57) . Furthermore, we have shown recently that T Reg expression of CD25 limits memory CD8 + T cell expansion by limiting availability of IL-2 (68) . We show in this study that CD25 plays a crucial role in the rapid response of T CM in Rag1 2/2 model system shown in this paper. Therefore, in the CD11c.OVA mice, imiquimod may decrease T Reg number, thus liberating available IL-2 for local memory T cell expansion. Mast cells may also play an important role in breaking tolerance in skin. Imiquimod increases mast cell number in the skin, whereas injection of the mast cell stimulating compound 48/80 induces rejection of skin grafts in CD11c.OVA mice recipient of T CM (S. Fiorenza, unpublished observations).
To our knowledge, this work presents the first comparative analysis of T CM -and T EM -mediated regression directed against skin and provides a mechanism underlying the rapid rejection of skin grafts expressing a foreign Ag by T CM . Furthermore, this is the first work we are aware of that provides a simple and clinically available intervention that differentially optimizes in vitro-derived T CM but not T EM function in the skin in a tolerogenic environment. The clinical implications of this work for future approaches to immunotherapy are significant. Understanding the in vivo function of adoptively transferred memory T cells in the skin is particularly important given the significant morbidity and mortality posed by cutaneous chronic viral infection in the skin and the potential of adoptive cell therapy to address this clinical problem (1, 3) . This work posits an effective strategy for the use of ex vivo-differentiated T CM in combination with a local inflammatory cue for immunotherapy in the skin in tolerogenic hosts.
